CD300lf is the primary physiologic receptor of murine norovirus but not human norovirus by Graziano, Vincent R et al.
Washington University School of Medicine 
Digital Commons@Becker 
Open Access Publications 
4-1-2020 
CD300lf is the primary physiologic receptor of murine norovirus 
but not human norovirus 
Vincent R. Graziano 
Forrest C. Walker 
Elizabeth A. Kennedy 
Ebrahim Hassan 
Arthur S. Kim 
See next page for additional authors 
Follow this and additional works at: https://digitalcommons.wustl.edu/open_access_pubs 
Authors 
Vincent R. Graziano, Forrest C. Walker, Elizabeth A. Kennedy, Ebrahim Hassan, Arthur S. Kim, Megan T. 
Baldridge, and et al. 
RESEARCH ARTICLE
CD300lf is the primary physiologic receptor of
murine norovirus but not human norovirus
Vincent R. GrazianoID
1, Forrest C. WalkerID
2, Elizabeth A. Kennedy2, Jin WeiID
1,
Khalil Ettayebi3, Madison S. StrineID
1, Renata B. Filler1, Ebrahim HassanID
2, Leon
L. HsiehID
4, Arthur S. KimID
2, Abimbola O. KolawoleID
5, Christiane E. WobusID
5, Lisa
C. Lindesmith6, Ralph S. Baric6, Mary K. EstesID
3, Robert C. OrchardID
7, Megan
T. BaldridgeID
2*, Craig B. WilenID1*
1 Departments of Laboratory Medicine and Immunobiology, Yale University School of Medicine, New Haven,
Connecticut, United States of America, 2 Department of Medicine, Division of Infectious Diseases, Edison
Family Center for Genome Sciences & Systems Biology, Washington University School of Medicine, Saint
Louis, Missouri, United States of America, 3 Departments of Medicine and Molecular Virology & Microbiology,
Baylor College of Medicine, Houston, Texas, United States of America, 4 Department of Molecular
Microbiology and Immunology, Bloomberg School of Public Health, Johns Hopkins University, Baltimore,
Maryland, United States of America, 5 Department of Microbiology and Immunology, University of Michigan
Medical School, Ann Arbor, Michigan, United States of America, 6 Department of Epidemiology, University of
North Carolina, Chapel Hill, North Carolina, United States of America, 7 Department of Immunology,
University of Texas Southwestern Medical School, Dallas, Texas, United States of America
* craig.wilen@yale.edu (CW); mbaldridge@wustl.edu (MTB)
Abstract
Murine norovirus (MNoV) is an important model of human norovirus (HNoV) and mucosal
virus infection more broadly. Viral receptor utilization is a major determinant of cell tropism,
host range, and pathogenesis. The bona fide receptor for HNoV is unknown. Recently, we
identified CD300lf as a proteinaceous receptor for MNoV. Interestingly, its paralogue
CD300ld was also sufficient for MNoV infection in vitro. Here we explored whether CD300lf
is the sole physiologic receptor in vivo and whether HNoV can use a CD300 ortholog as an
entry receptor. We report that both CD300ld and CD300lf are sufficient for infection by
diverse MNoV strains in vitro. We further demonstrate that CD300lf is essential for both oral
and parenteral MNoV infection and to elicit anti-MNoV humoral responses in vivo. In mice
deficient in STAT1 signaling, CD300lf is required for MNoV-induced lethality. Finally, we
demonstrate that human CD300lf (huCD300lf) is not essential for HNoV infection, nor does
huCD300lf inhibit binding of HNoV virus-like particles to glycans. Thus, we report huCD300lf
is not a receptor for HNoV.
Author summary
Human norovirus is the leading cause of non-bacterial gastroenteritis causing up to
200,000 deaths each year. How human norovirus enters cells is unknown. Because human
norovirus is difficult to grow in the laboratory and in small animals, we use mouse or
murine norovirus as a model system. We recently discovered that murine norovirus can
use the either CD300ld or CD300lf as a receptor in vitro. We also showed that CD300lf
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deficient mice were resistant to oral challenge with a single virus strain. Here we deter-
mined that CD300lf is essential for infection of diverse murine norovirus strains in cell
lines and in mice with normal immune systems demonstrating it’s the primary physio-
logic receptor for diverse murine norovirus strains independent of infection route. Finally,
we demonstrated that human CD300lf is not the elusive proteinaceous receptor for
human norovirus.
Introduction
Human norovirus (HNoV) is the leading cause of infectious gastroenteritis globally, yet our
understanding of how HNoV enters cells is limited[1–4]. Viral entry is the first and often rate-
limiting step of the viral life cycle and is a major determinant of cell tropism, species range,
host genetic susceptibility, and pathogenesis[1,5]. Entry includes virion attachment to the host
cell membrane, receptor engagement, internalization, and genome release into the cell cyto-
plasm[1,5]. Both histo-blood group antigens (HBGAs) and bile salts bind HNoV and promote
infection[6–8]. The identity of a proteinaceous cellular receptor(s) for HNoV remains
unknown[1,8,9].
Murine norovirus (MNoV) represents a surrogate animal model for studies of HNoV infec-
tion and pathogenesis[1,10,11]. In contrast to HNoV, diverse infectious molecular clones exist
for MNoV that can be readily propagated both in vitro and in mice. MNoV and HNoV share
similar genome and capsid architecture, fecal-oral transmission routes, interactions with bile
salts, and the ability to cause both acute and persistent infection[1,7,8,10–14]. Recently, we
identified CD300 family members CD300ld and CD300lf as functional receptors for MNoV
[15,16]. CD300lf is necessary for infection of MNoV-susceptible RAW 264.7 and BV2 cell
lines while both CD300ld and CD300lf are sufficient to confer susceptibility to cell lines from
different species when ectopically expressed[15,16]. In addition, CD300lf-deficient mice are
resistant to fecal-oral transmission of MNoV strain CR6 (MNoVCR6)[15]. Whether CD300lf is
essential for genetically diverse MNoV strains, parenteral infection routes, or in the setting of
immunodeficiency is unclear. Finally, it is unknown whether human CD300lf functions as a
receptor for HNoV.
Noroviruses are non-enveloped, positive-sense single-stranded RNA viruses[1]. The viral
capsid exhibits T = 3 icosahedral symmetry and is comprised of 90 dimers of the major struc-
tural protein VP1[17]. VP1 contains a shell (S) domain and a protruding (P) domain that con-
tains a proximal P1 and distal P2 subdomain[18]. P2 is the target for several neutralizing
monoclonal antibodies for both HNoV and MNoV and contains the receptor binding site for
MNoV[12,13]. Co-crystal structures and mutagenesis studies have identified that the CC’ and
CDR3 loops of CD300lf directly bind to a cleft between the AB’ and DE’ loops of the MNoV
VP1 P2 subdomain[13,15,19]. Each CD300lf binds one P2 monomer, albeit at relatively low
affinity, suggesting that norovirus-receptor interactions are largely driven by avidity[13]. Inter-
estingly, binding of MNoV to CD300lf is promoted by both divalent cations and bile salts
[12,13,15].
Diverse MNoV strains have been described with distinct pathogenic properties[20–22].
Specifically, MNoVCW3 causes acute systemic infection that is cleared by the adaptive immune
system, while other strains including MNoVCR6 cause chronic enteric infection that can persist
for months, if not the life of the animal[20,23]. Interestingly, a single amino acid in the P2
domain of MNoV VP1 is sufficient to confer lethality in mice deficient in type I interferon sig-
naling, suggesting a role for virus-receptor interactions in determining pathogenesis[20,24].
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There are eight CD300 family members in mice and seven in humans, each containing a
conserved ectodomain, a single transmembrane domain, and a more variable cytoplasmic sig-
naling domain[25,26]. The ectodomains bind diverse phospholipids found on dead and dying
cells, resulting in activating or inhibitory signals depending upon the cellular and molecular
context[26–30]. Both CD300ld and CD300lf are expressed in diverse myeloid cells, while
CD300lf is additionally expressed in lymphoid cells and rare intestinal epithelial cells called
tuft cells, which are the primary target cell of MNoVCR6 [25,31].
Several important questions remain regarding norovirus entry: is CD300lf the only receptor
in vivo? Do other CD300 family members such as CD300ld contribute to infection? Does
HNoV use CD300lf as a receptor? Here we show that CD300lf is essential for fecal-oral trans-
mission and pathogenesis of diverse MNoV strains in both immunocompetent and immuno-
deficient mice, suggesting CD300lf is the primary physiologic receptor for MNoV. We also
identify CD300lf-independent viral infection in the setting of extra-intestinal challenge in
immunodeficient mice, suggesting a potential role for CD300ld or other receptors in this non-
physiological infection route. Finally, we demonstrate that CD300lf and related CD300 family
members do not function as HNoV receptors.
Results
HNoV induces vomiting and diarrhea within approximately 24 hours after infection[32–34].
In contrast, MNoV replicates to high titers but is largely avirulent in immunocompetent mice
[10,35,36]. We previously demonstrated that Cd300lf-/- mice do not shed detectable MNoVCR6
between 3 and 21 days after per oral (PO) challenge; however, the role of CD300lf and poten-
tial role of CD300ld during earlier time points and in systemic tissues is unknown[15].
MNoVCW3 is an infectious molecular clone derived from the MNV-1 plaque isolate CW3
[14,20]. MNoVCW3 can infect myeloid and lymphoid cells in the intestine and secondary lym-
phoid organs and cause lethal infection in mice deficient in type I interferon signaling
[14,20,37,38]. To test whether CD300lf was essential for MNoVCW3 infection ex vivo, we chal-
lenged bone marrow-derived macrophages (BMDMs) from Cd300lf+/- or Cd300lf-/- mice with
MNoVCW3. Cd300lf-/- BMDMs did not produce infectious virus as measured by plaque assay
(Fig 1A) nor did they express the MNoV non-structural protein NS1/2 as detected by flow
cytometry (Fig 1B and 1C). CD300lf is thus essential for MNoVCW3 infection of murine
BMDMs. To test the role of CD300lf in vivo, we challenged Cd300lf+/- and Cd300lf-/- littermate
mice with 106 plaque forming units (PFU) of MNoVCW3 perorally (PO) and measured infec-
tious virus by plaque assay (Fig 1D). We also quantified viral genomes by qPCR (Fig 1E). At 24
hours post-infection (hpi), infectious virions were undetectable in Cd300lf-/- mice in the
mesenteric lymph node (MLN), ileum, and colon, in contrast to Cd300lf+/- littermates. At this
dose and time point, MNoVCW3 was not detected in the spleen of control or knockout mice.
Viral genomes were similarly undetectable in Cd300lf-deficient animals (Fig 1E).
Different MNoV strains have different in vivo tissue and cellular tropism, supporting the
possibility that they may utilize distinct cellular attachment and entry mechanisms[31,38,39].
Next, we asked whether CD300lf was required for infection by genetically diverse MNoV
strains. MNoV strains are derived from a single genogroup (Genogroup V) and alignments of
MNoV VP1 previously revealed at least five distinct clusters, from which we selected represen-
tative strains MNoVCW3, MNoVCR6, MNoVWU23, MNoVCR3, and MNoVCR7 (Table 1) [21,40–
42]. An alignment of strains highlights conserved regions of the capsid protein, including the
CD300lf binding sites and bile-acid interacting sites described previously (S1 Fig)[13]. Among
these strains, there is 84% amino acid identity in the P domain and 98% amino acid identity in
the more conserved S domain. The 11 VP1 residues shown to interact with the secondary bile
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salts glycochenodeoxycholic acid (GCDCA) or lithocholic acid (LCA) are perfectly conserved
[13]. However, there is variation in 4 of the 17 VP1 residues previously shown to interact with
CD300lf[13].
These data suggest that diverse strains may utilize receptors other than CD300lf (S1 Fig)
[13]. To test the hypothesis that diverse MNoV strains differentially utilize CD300lf, we first
Fig 1. CD300lf is necessary for MNoVCW3 infection ex vivo and in vivo. (A-C) BMDMs were generated from Cd300lf-/- and
Cd300lf+/- littermate controls. (A) BMDMs were challenged with MNoVCW3 (MOI = 0.05) and viral replication was measured by
plaque assay 24 hpi. (B) Cd300lf+/- and Cd300lf-/- BMDMs were challenged with MNoVCW3 (MOI = 5) and expression of the MNoV
non-structural protein NS1/2 was measured by flow cytometry. (C) Quantification of NS1/2 expression. (D-E) Cd300lf+/- and
Cd300lf-/- littermates were challenged with 106 PFU PO MNoVCW3. 24 hpi, virus was measured by both (D) plaque assay and (E)
qPCR in the MLN, spleen, distal ileum, and proximal colon. Data was analyzed by Mann-Whitney test. Shown are means ± SEM.
NS, not significant; �P<0.05; ��P<0.01; ���P<0.001; L.O.D., limit of detection. Experiments in (A-C) where performed at least two
independent times each in triplicate. Data in (D-E) are pooled from two independent experiments with at least three mice per group.
https://doi.org/10.1371/journal.ppat.1008242.g001
Table 1.
Virus Source mouse Source tissue Chronic infection Systemic infection Fecal Shedding Accession Ref
CW3 IFNαβγR–/– Brain No Yes Limited EF014462.1 [14,20,55]
CR6 B6 variant Feces Yes No Yes EU004676.1 [21]
CR3 B6 variant Feces Yes No Yes EU004676.1 [21]
CR7 B6 variant Feces Yes No Yes EU004677 [21]
WU23 B6.OT1/ Rag1-/-/IFNγR-/- Feces Unknown Yes Yes EU004668 [21]
MNV-3 Pooled MLN Yes No Yes JQ658375.1 [56]
S99 YFPH tg Feces Yes No Yes EF531291 [21,41]
B6, C57BL/6; B6 variant, unknown C57BL/6 genetically modified mouse; YFPH tg, Yellow fluorescent protein transgenic.
https://doi.org/10.1371/journal.ppat.1008242.t001
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tested whether CD300lf was necessary and sufficient for infection by these strains in vitro. We
challenged CD300lf-deficient BV2 microglial cells, which are pan-susceptible to all known
MNoV strains, with six diverse MNoV strains. All strains induced cytopathic effects in wild-
type BV2 cells but not CD300lf-deficient cells, demonstrating CD300lf is essential for virus
induced-lethality in BV2 cells (Fig 2A). Next, we asked whether CD300ld and CD300lf are suf-
ficient to confer susceptibility to human HeLa cells, which are not normally susceptible to
MNoV as they lack expression of murine CD300 proteins. Consistent with our prior findings,
both CD300ld and CD300lf are sufficient for infection by MNoVCW3 as measured by expres-
sion of the MNoV non-structural protein NS6/7 by flow cytometry[15]. Similarly, both
CD300ld and CD300lf are sufficient for MNoVWU23, MNoVCR3, MNoVCR7, MNoVMNV3, and
MNoVS99 infection (Fig 2B). All tested MNoV strains utilize CD300ld and CD300lf at similar
efficiencies when overexpressed in HeLa cells.
To determine whether CD300lf was essential for infection in vivo, we challenged Cd300lf+/-
and Cd300lf-/- littermates with 106 PFU PO of either MNoVCW3, MNoVCR6, MNoVWU23,
MNoVCR3, or MNoVCR7 and measured viral genomes seven days post-infection (dpi). These
viruses represent each of the five distinct MNoV VP1 phylogenetic clusters described previ-
ously[40]. MNoVCW3 causes acute systemic infection that is cleared by 10–14 dpi, while
MNoVCR6, MNoVCR3, and MNoVCR7 cause persistent infection[21]. The in vivo characteris-
tics of MNoVWU23 are uncharacterized[21]. Consistent with prior studies, we observed differ-
ential tissue tropism associated with different MNoV strains[21]. In CD300lf+/- control mice,
viral genomes for all tested MNoV strains were shed in the feces of some mice with the excep-
tion of MNoVCW3 (Fig 2C). All tested MNoV strains were detected in the MLN (Fig 2D). All
strains were detectable albeit at varying levels in the ileum and colon. Interestingly, only
MNoVCW3 and MNoVWU23 were detectable in the spleen. MNoVCR6, MNoVCR3, and
MNoVCR7, which are known to establish chronic infection in immunocompetent mice did not
have detectable viral genomes in the spleen. MNoV genomes were not detected in any tissue
(MLN, spleen, ileum, colon, or feces) of any Cd300lf-deficient mice challenged with any of the
five MNoV strains (Fig 2C–2G). To determine whether there was MNoV infection below the
limit of detection, we collected feces from Cd300lf+/- or Cd300lf-/- mice challenged with
MNoVCR6 seven days prior, and then gavaged the feces into Stat1-/- recipient mice which lack
innate immunity and are exquisitely sensitive to MNoV infection[14,15]. Seven days after fecal
gavage we detected MNoVCR6 in Stat1-/- mice challenged with feces from Cd300lf+/- mice but
not from Cd300lf-/- mice (Fig 2H). These results suggest CD300lf is critical for infection by
diverse MNoV strains in immunocompetent mice in vivo.
To further determine whether CD300ld or an alternative receptor was sufficient for MNoV
infection below our limit of detection, we assessed the humoral immune response against
MNoVCW3 at 14 days dpi, a time point after viral clearance by the adaptive immune system. A
1:10 dilution of sera from Cd300lf+/- mice that cleared MNoVCW3 infection neutralized
MNoVCW3 in vitro as measured by BV2 cell viability (Fig 3A). The IC50 from Cd300lf+/- mice
was approximately 1:80 in contrast to sera from Cd300lf-/- mice which did not reach an IC50
(Fig 3B). To determine whether MNoVCW3 elicited a non-neutralizing humoral response in
Cd300lf-/- mice, we measured anti-MNoV IgG and IgM in the sera. Cd300lf+/- mice had a sig-
nificantly higher anti-MNoV IgG and IgM response consistent with resistance of Cd300lf-/-
mice to MNoVCW3 infection (Fig 3C and 3D).
Next, we asked whether CD300lf was essential for fecal-oral transmission of MNoVCW3 in
Stat1-/- mice. We challenged Cd300lf+/+, Cd300lf+/- or Cd300lf-/- mice on a Stat1-/- background
with 106 PFU MNoVCW3 PO, which is greater than 1000-fold above the lethal dose[15]. All
Cd300lf+/+Stat1-/- succumbed to lethal infection by five dpi (Fig 4A). Cd300lf+/-Stat1-/- simi-
larly all died but with a one-day delay in death suggesting a modest CD300lf gene dosage effect
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Fig 2. CD300lf is necessary and sufficient for infection by diverse MNoV strains. (A) CD300lf WT and KO BV2 cells
were infected with MNoV strains CW3, WU23, CR3, CR7, MNV-3, and S99 at a MOI of 5. CD300lf KO BV2 cells were
protected from virus-induced cell death for all MNoV strains. (B) Mouse CD300ld (muCD300ld) and CD300lf
(muCD300lf) were overexpressed in human HeLa cells by transient transfection. Cells were challenged with MNoV
strains at a MOI of 5 for 24 hours and then infection was quantified by MNoV NS6/7 expression by flow cytometry.
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on MNoV pathogenesis. In contrast, all ten Cd300lf-/-Stat1-/- mice survived until at least 21 dpi
without overt clinical manifestations (Fig 4A).
Given the distinct target cell types, tissue tropism, and pathogenesis between MNoV strains,
we next tested whether Cd300lf-/-Stat1-/- mice were susceptible to MNoVCR6 infection. In con-
trast to MNoVCW3, MNoVCR6 is not lethal in Stat1-/- mice although the virus replicates to
higher titers and can spread to extra-intestinal tissues[14]. All Cd300lf+/+Stat1-/- and
Cd300lf+/-Stat1-/- mice challenged with 106 PFU PO MNoVCR6 survived the seven-day infec-
tion. Viral genomes were detected in the feces, MLN, spleen, ileum, and colon (Fig 4B–4F).
There was a modest CD300lf gene dosage effect in the spleen (p<0.05) among Cd300lf+/+ and
(C-H) Cd300lf+/- or Cd300lf-/- mice were challenged with 106 PFU PO CW3, WU23, CR6, CR3, or CR7 for seven days.
MNoV was detectable in the (C) feces, (D) MLN, (E) spleen, (F) ileum, and (G) colon of Cd300lf+/- but not Cd300lf-/-
mice. (H) To test whether CR6 was shed in feces below the limit of detection by qPCR, we gavaged Stat1-/- mice with
feces from Cd300lf+/- or Cd300lf-/- mice challenged with MNoVCR6 from (C). Fecal pellets from Cd300lf-/- mice, did not
establish detectable infection in Stat1-/- mice. Data is pooled from two to four independent experiments. Data was
analyzed by Mann-Whitney test. Shown are means ± SEM. NS, not significant; �P<0.05; ��P<0.01; ���P<0.001; L.O.D.,
limit of detection.
https://doi.org/10.1371/journal.ppat.1008242.g002
Fig 3. CD300lf is required to generate humoral response after oral MNoVCW3 challenge. Sera was collected from
Cd300lf+/- and Cd300lf-/- mice 14 days after challenge with 106 PFU PO MNoVCW3. (A) The maximal protection (1:10
sera dilution) and (B) sera IC50 was measured by in vitro MNoVCW3 neutralization assay in BV2 cells. (C) Cd300lf+/-
generated significantly increased anti-MNoV IgG (C) and IgM (D). Data is pooled from two independent experiments.
Data was analyzed by Mann-Whitney test. Shown are means ± SEM. NS, not significant; �P<0.05; ��P<0.01;
���P<0.001; ����P<0.0001. L.O.D., limit of detection.
https://doi.org/10.1371/journal.ppat.1008242.g003
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Cd300lf+/- mice, but this was not statistically significant in the MLN, ileum, colon, or feces
(Fig 4C–4F). Relative to Stat1+/+ mice, viral genome copies were elevated and extra-
intestinal spread to the spleen was observed consistent with prior findings (Fig 2C–2G).
Importantly, Cd300lf-/-Stat1-/- mice were resistant to MNoVCR6 in all tissues examined. Two
Fig 4. CD300lf is essential for oral MNoV transmission in Stat1-/- mice. (A) Cd300lf+/+Stat1-/- (N = 8) and Cd300lf+/-Stat1-/- (N = 4) mice
challenged with 106 PFU PO MNoVCW3 succumbed to infection by 5 and 6 dpi, respectively. In contrast, all Cd300lf-/-Stat1-/- (N = 10) mice
survived for at least 21 dpi. (B-F) Cd300lf+/+Stat1-/-, Cd300lf+/-stat1-/-, and Cd300lf-/-Stat1-/- mice were challenged with 106 PFU PO MNoVCR6. All
mice survived infection. Viral genomes were quantified in the (B) feces, (C) MLN, (D) spleen, (E) ileum, and (F) colon at seven dpi. Data is pooled
from at least three independent experiments. Data was analyzed by Mann-Whitney test and Kaplan-Meier curves were generated for survival
experiments. Shown are means ± SEM. NS, not significant; �P<0.05; ��P<0.01; ���P<0.001; ����P<0.0001. L.O.D., limit of detection.
https://doi.org/10.1371/journal.ppat.1008242.g004
PLOS PATHOGENS CD300lf is the primary receptor of murine norovirus
PLOS Pathogens | https://doi.org/10.1371/journal.ppat.1008242 April 6, 2020 8 / 19
Cd300lf-/-Stat1-/- mice had detectable viral genomes in the MLN but not in other tissues (Fig
4C). A third mouse had detectable low-level viral RNA in the colon but not in any other tissue,
possibly reflective of input virus or a false positive (Fig 4F).
The natural defenses of the gastrointestinal mucosa represent a bottleneck to viral infection.
To test whether CD300lf was essential for parenteral infection routes, we bypassed the gastro-
intestinal tract by administering 107 PFU MNoVCW3 intraperitoneally (IP) to Cd300lf-/-Stat1-/-
mice. All Cd300lf+/+Stat1-/- and Cd300lf+/-Stat1-/- mice died by five or six dpi, respectively (Fig
5A). Two of nine Cd300lf-/-Stat1-/- mice died at 10 and 14 dpi with the remaining mice surviv-
ing at least 21 days. The two Cd300lf-/-Stat1-/- mouse deaths were observed in independent
experiments. Virological data was not available from these animals; therefore, whether
MNoVCW3 contributed to the death of these two Cd300lf-/-Stat1-/- mice is unknown.
Next, we challenged mice with 107 PFU MNoVCR6 IP. In contrast to the lower- dose
MNoVCR6 administered PO, 77% (7/9) of Cd300lf+/+Stat1-/- mice and 66% (2/3)
Cd300lf+/-Stat1-/- mice died (Fig 5B). All six Cd300lf-/-Stat1-/- mice survived IP infection with
107 MNoVCR6 until sacrifice at seven dpi. Interestingly, MNoVCR6 genomes were detected in
the MLN, spleen, ileum, and colon of Cd300lf-/-Stat1-/- mice (Fig 5C). MNoVCR6 from
Cd300lf-/-Stat1-/- mice infected with 107 PFU MNoVCR6 IP was Sanger sequenced, revealing a
single nucleotide change (T6595A) resulting in a phenylalanine to isoleucine mutation at posi-
tion 514 (F514I) in the P1 domain of VP1 (S1 Fig). This mutation was detected in the spleen of
three out of three Cd300lf-/-Stat1-/- mice and three out of four Cd300lf+/+Stat1-/- or
Cd300lf+/-Stat1-/- mice analyzed. This mutation did not predominate in the ileum and colon of
these same animals. Thus, while CD300lf is essential for MNoV infection by oral inoculation
in immunocompetent hosts, CD300lf-independent replication of MNoV may occur albeit at
reduced efficiency under high-dose IP challenge in Stat1-/- mice.
Next, given the structural and genetic similarity between MNoV and HNoV, we tested
whether human CD300lf (huCD300lf) is a receptor for HNoV. First, we assessed the ability of
huCD300lf to prevent binding of recombinant HNoV virus-like particles (VLPs) to HBGAs in
pig gastric mucin. To increase the avidity of the potential CD300lf and VLP interaction, we
generated Fc-fusion proteins with the either huCD300lf or human CD300ld (huCD300ld)
ectodomains. We recently demonstrated that an Fc-fusion protein of mouse CD300lf has sub-
stantially increased binding and neutralizing ability on MNoV[13]. We incubated HNoV
VLPs with 10 μg/ml of either Fc-huCD300lf, Fc-huCD300ld, or a buffer-only control and mea-
sured HBGA-bound VLPs by ELISAs. Neither Fc-huCD300lf or Fc-huCD300ld inhibited
binding of GI.1 Norwalk, GI.3 Desert Shield Virus, GII.4 1997, or GII.4 2012 VLPs to HBGAs
(Fig 6A)[43,44]. Next, we asked whether potential HNoV interactions with huCD300lf were
necessary for infection of human intestinal enteroids (HIEs). Differentiated monolayers of
HIEs were incubated with polyclonal anti-huCD300lf or an IgG1 control and then challenged
with HNoV GII.4 from stool filtrate. We previously demonstrated that a similar polyclonal
anti-muCD300lf potently inhibited MNoV infection[15]. Anti-huCD300lf had no effect on
HNoV genome replication at 24 hpi relative to the isotype control (Fig 6B). Finally, we asked
whether Fc-huCD300lf could neutralize HNoV GII.4. Virus was pre-incubated with up to
50 μg/ml of Fc-huCD300lf and then used to infect HIEs. Fc-huCD300lf did not affect viral
genome replication relative to a control protein (Fig 6C). Together these data indicate that
huCD300lf is not a receptor for HNoV.
Discussion
Here we demonstrate that CD300lf, and not CD300ld, is the primary physiologic receptor for
diverse MNoV strains in vivo. We demonstrated that CD300lf is essential for detectable viral
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infection at multiple time points with diverse MNoV strains as measured by plaque assay,
qPCR, and serologic response. Interestingly, both CD300ld and CD300lf are sufficient to
mediate MNoV entry when ectopically expressed in vitro yet CD300ld is not sufficient for oral
or parenteral transmission in immunocompetent mice. Several possibilities may explain this
discordance. First, CD300ld receptor utilization has only been described when overexpressed
at supraphysiologic levels[15,16]. Similarly the soluble recombinant ectodomain of CD300lf
can neutralize MNoV infection in contrast to that of CD300ld[15]. This raises the possibility
that CD300ld utilization by MNoV is inefficient relative to CD300lf and that our overexpres-
sion assays are not sufficiently sensitive to quantify differences in receptor utilization effi-
ciency. A similar phenomenon has been described with HIV-1, which can engage co-receptors
other than CCR5 and CXCR4 when overexpressed in cell lines, but not under physiologically
relevant conditions[45,46]. Second, CD300ld and CD300lf have overlapping yet distinct cell
type expression, raising the possibility that CD300ld-expressing cells are either not permissive
to MNoV because of a post-entry restriction or because CD300ld-expressing cells are not
anatomically accessible to MNoV. Consistent with this, intestinal tuft cells, which are the
major target of MNoVCR6 in the intestines, express CD300lf but not CD300ld[31,47].
Although we demonstrated that Cd300lf-deficient mice are resistant to diverse MNoV
strains via both oral and parenteral routes, we observed detectable viral genomes in
Cd300lf-/-Stat1-/- mice inoculated with high-dose MNoVCR6 IP, consistent with CD300lf-inde-
pendent viral replication. Sanger sequencing of virus from tissues from multiple mice revealed
a single amino acid mutation (F514I) in the P1 domain of MNoV VP1 of Stat1-/-mice with and
without a functional copy of CD300lf, suggesting this variant emerged independent of
CD300lf interactions. This raises the question as to why this viral variant emerged and whether
it has physiologic relevance, to be explored in future studies.
The physiologic function of CD300lf is as a cell death sensor and immunoregulatory pro-
tein[25]. Interestingly, the CD300 locus is under positive selection and there are a number of
CD300lf polymorphisms in laboratory and wild mouse strains that may affect CD300lf expres-
sion or conformation and thus may regulate susceptibility to MNoV[48]. This raises the
intriguing hypothesis of a molecular arms race between MNoV and mice over evolutionary
Fig 5. CD300lf is essential for pathogenesis of parenterally transmitted MNoV in STAT1 deficient mice. (A) Mice were
challenged with 107 PFU IP MNoVCW3. Cd300lf-/-Stat1-/- mice (N = 9 mice) survived infection in contrast to Cd300lf+/+Stat1-/-
(N = 15 mice) and Cd300lf+/-Stat1-/- (N = 9 mice) littermates. (B) Mice were challenged with 107 PFU IP MNoVCR6. Cd300lf-/-Stat1-/-
mice (N = 6 mice) survived infection in contrast to Cd300lf+/+Stat1-/- (N = 9 mice) and Cd300lf+/-Stat1-/- (N = 3 mice) littermates.
(C) MNoV genomes were quantified from the MLN, spleen, ileum, and colon of Cd300lf-/-Stat1-/- mice seven days post-challenge
with 107 PFU IP MNoVCR6. Data was analyzed by Kaplan-Meier curve for survival experiments. Data is pooled from at least three
independent experiments with 1–5 mice per group. �P<0.05; ��P<0.01; ���P<0.001; ����P<0.0001. L.O.D., limit of detection.
https://doi.org/10.1371/journal.ppat.1008242.g005
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time which may have contributed to the relatively non-pathogenic consequences of MNoV in
immunocompetent mice.
Finally, these data have several important implications for our understanding of HNoV, the
entry mechanisms of which remain to be defined. Given the structural similarity between
MNoV and HNoV as well as mouse and human CD300lf, we hypothesized that human
CD300lf might be a functional receptor for HNoV. However, via multiple orthogonal
approaches we demonstrated that human CD300lf is not a functional receptor for several GI
and GII HNoVs. This further raises the question as to the identity of the HNoV receptor and
whether or not it is structurally related to CD300lf. This remains an important area of future
investigation that would significantly enhance our understanding of HNoV pathogenesis and
facilitate novel prophylactic and therapeutic approaches.
Fig 6. Human CD300lf is not a HNoV entry factor. (A) Human CD300lf and human CD300ld Fc-fusion proteins do not
prevent binding of HNoV virus-like particles (VLPs) to pig gastric mucin for GI.1 Norwalk, GI.3 Desert Shield Virus, GII.4.1997,
and GII.4.2012. (B) Polyclonal antibody against human CD300lf does not prevent HNoV GII.4 replication in HIEs relative to an
IgG1 control. (C) Pre-incubating HNoV GII.4 with a human CD300lf Fc-fusion protein does not prevent HNoV replication in
HIEs relative to a control protein (RV NSP4). Data in (A) is representative of at least two independent replicates each performed
in duplicate. Data in (B and C) is pooled from three independent experiments with each condition and time point performed in
triplicate wells of HIE cultures. Shown are means ± standard deviation.
https://doi.org/10.1371/journal.ppat.1008242.g006
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Materials and methods
Mouse strains
All mouse strains used in this experiment were from a C57BL/6J background (Jackson Labora-
tories, Bar Harbor, ME) and bred in-house. Generation of B6.CD300lfem1Cbwi/J (Cd300lf-/-)
mice (Jackson Laboratories) and B6.129S(Cg)-Stat1tm1Div/J (Stat1-/-) (gift of H.W. Virgin)
were previously described[15,49]. These mice were housed in a MNoV-free facility at Yale
University School of Medicine. All experiments used littermate controls, were gender-bal-
anced, and done at least two independent times. Mice were used for infections between 6–10
weeks of age. Genotyping of mice was done by real time PCR as described previously[15].
Ethics statement
The care and use of the animals were approved by and in agreement with the Yale Animal
Resource Center and Institutional Animal Care and Use Committee (#2018–20198) according
to standards in the Animal Welfare Act.
Viral stocks
MNoVCW3 (Gen bank accession EF014462.1), MNoVCR6 (accession JQ237823), and
MNoVMNV3 (accession JQ658375.1) were generated from infectious molecular clones.
MNoVCW3 is a plaque derived isolate of MNV-1[20]. Plasmids containing infectious molecular
clones were transfected into 293T cells (ATCC) to generate a P0 stock as previously described
[15,20,50]. The P0 virus was passaged in BV2 cells (gift of H.W. Virgin) to create a P1 stock
that was used to inoculate BV2 cells at a 0.05 multiplicity of infection (MOI) for 36 hours to
generate a working P2 stock. MNoVWU23 (accession EU004668), MNoVCR3 (accession
EU004676.1), MNoVCR7 (accession EU004677), MNoVS99 (accession EF531291) were pas-
saged RAW 264.7 cells (ATCC SC-6003) up to six times. RAW cell-derived virus was then
expanded one time in BV2 cells as described above. Infected BV2 cell cultures were freeze/
thawed, cell debris was pelleted at 1200g for 5 minutes (min), supernatant was filtered through
a 0.22 μm filter and concentrated through a 100,000 MWCO Amicon Ultra filter. Virus stocks
were aliquoted, tittered three independent times in duplicate, and stored at -80˚C until use
[15]. Sequencing of the MNoV capsid was performed by PCR amplification from viral cDNA
using primers 5’-AACAACTTCACGGTCCAGTCGG3’ and 5’-GCTTGAAAGAGTTGGCTT
GGAGC-3’ followed by Sanger sequencing by GENWIZ (South Plainfield, NJ). MNoV VP1
alignment was performed with ESpript 3.0 software.
Cell line culture
BV2 cells, 293T cells, and HeLa cells (ATCC) were maintained in Dulbecco’s modified eagle
media (DMEM; Gibco, Gaithersburg, MD) supplemented with 10% fetal bovine serum (FBS;
VWR, Radnor, PA), 1% pen/strep (Gibco), and 1% HEPES (Gibco). CD300lf-deficient BV2
cells (clone 1B6, BV2ΔCD300lf) were generated by CRISPR/Cas9[15]. BV2ΔCD300lf cells
were complemented with transgenic CD300lf as described previously[15]. HIE cultures (Bay-
lor College of Medicine) were maintained as previously described[8]. BL6/J bone marrow pro-
genitors were isolated from CD300lf-/- or CD300lf+/- mice as previously described[15,51].
Progenitors were differentiated into BMDMs by plating 106 cells into a 10 cm non-tissue cul-
ture treated dish with BMDM media (DMEM, 10% fetal bovine serum, 10% CMG14 condi-
tioned media, 1 mM sodium pyruvate, 2 mM L-glutamine, 1% pen/strep) and incubated for
seven days at 37˚C and 5% CO2[52]. BMDM differentiation was confirmed by flow cytometry
staining for F4/80.
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In vitro MNoV infections
BV2-WT and BV2ΔCD300lf cells (gift of H.W. Virgin) were seeded at 20,000 cells per well in
96-well plates and infected with diverse MNoV strains at a MOI of 5. After 48 hours, 25μL of
CellTiter-Glo (Promega, Madison, WI) was added to each well and luminescence was detected
on a Synergy luminometer (BioTek). Experiments were performed in duplicate in at least
three independent experiments. BMDMs were infected for 24 hours with MNoVCW3 at a MOI
5 for flow cytometry experiments and a MOI 0.05 for plaque assays. Human enteroids were
inoculated with HNoV GII.4 from stool filtrate as described previously[8]. Tranfected 293T
cells were challenged with HNoV GII.6 from stool filtrate as described below. The HNoV
GII.6 stool filtrate was determined to be infectious using BJAB cells as described previously[9].
In vitro HNoV infections in HIEs
Five-day differentiated jejunal HIE monolayers in 96-well plates were inoculated with GII/Hu/
US/2012/GII.4 Sydney [P31]/TCH12-580 (2.5x105 genome copies/well) from stool filtrate as
described previously[8]. This virus has no accession number as it is from a stool filtrate. Exper-
iments were conducted in triplicate in three independent experiments. Serial dilutions of poly-
clonal antibody against the huCD300LF ectodomain (R&D Systems; AF2774) or recombinant
human CD300LF/LMIR3 Fc chimera protein (R&D Systems; 2774-LM-050) samples were car-
ried out in CMGF(-) medium containing 500 μM glycochenodeoxycholic acid (GCDCA). An
isotype control (Recombinant Human IgG1 Fc, CF; R&D Systems; 110-HG-100) and recombi-
nant rotavirus NSP4 protein were used as controls respectively. GII.4_Sydney_2012 (2.5x105
genome copies) were mixed with an equal volume of media or dilutions of each serum or pro-
tein sample at 37˚C for 1 hr, and inoculated onto jejunal HIE monolayers for another 1 hr at
37˚C in 5% CO2. After incubation, monolayers were washed twice with CMGF(-) media to
remove unbound virus and cultured in differentiation media with 500 μM GCDCA for the
indicated time points. RNA was extracted from each well using the KingFisher Flex Purifica-
tion system and MAgMAX-96 Viral RNA Isolation kit. RNA extracted at 1 hpi, was used as a
baseline to determine the amount of input virus that remained associated with cells after wash-
ing the infected cultures to remove the unbound virus. Replication of virus was determined by
RNA levels quantified from samples extracted at 24 hpi.
Mouse infections
Mice were perorally (PO) inoculated with 25μL of 106 PFU MNoV diluted in D10 (DMEM
with 10% FBS). For intraperitoneal (IP) challenge, MNoV was diluted to either 107 PFU per
200μL in phosphate buffered saline (PBS) and injected into the left lower quadrant of the peri-
toneal cavity with an insulin syringe. Fecal transmission assay was performed by infecting
Cd300lf-/- or Cd300lf+/- mice with 25μL PO of 106 PFU MNoVCR6. At seven dpi, a freshly iso-
lated fecal pellet was homogenized in 100μL of PBS and 25μL of the fecal slurry was adminis-
tered PO to Stat1-/- mice. Seven days after fecal transfer, fecal samples from the Stat1-/-
recipient mice were tested for MNoV genomes via qPCR as described below.
Virus quantification by plaque assay
BV2 cells were seeded in 6-well plates at 2 x106 cells/well. Tissue samples were weighed and
homogenized with 1.0 mm silica beads (BioSpec, Bartlesville, OK) in 1 mL of D10 with 1% Pen/
Strep, and 1% HEPES[38]. Tissue homogenates were serially diluted ten-fold. Media was aspi-
rated off the BV2 cells and samples were inoculated to each well and gently rocked for 1 hour.
Inoculum was removed and 2 mL of overlay media (MEM containing 1% methylcellulose, 10%
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FBS, 1% GlutaMAX (Gibco), 1% HEPES, and 1% pen/strep) was added to each well. Inoculated
plates were incubated for 48 hours at 37˚C and 5% CO2 prior to plaque visualization with crys-
tal violet (0.2% crystal violet in 20% ethanol) as described previously[37]. Plaque assay from cell
culture was performed by freeze/thawing infected samples at 0, 12, and 24 hpi followed by serial
dilutions as described above[15,37].
Quantitative PCR
MNoV genome copies in fecal pellets and tissues were determined as previously described
[15,53]. Briefly, viral RNA from fecal pellets was extracted using the Quick-RNA Viral 96 Kits
according to manufacturer’s protocol (Zymo Research, Irvine, CA). Tissue RNA extraction
was performed using TRIzol (Life Technologies, Carlsbad, CA) and purified using Direct-zol
RNA MiniPrep Plus according to manufacturer’s instructions (Zymo Research). A two-step
cDNA synthesis with 5μl RNA, random hexamer, and ImProm-II Reverse Transcriptase (Pro-
mega) was performed[31]. Then, qPCR analysis was performed in duplicate for each of the
samples and standard curves generated using MNoV specific oligonucleotides: Probe: 5’
6FAM-CGCTTTGGAACAATG-MGBNFQ 3’; Forward primer: 5’ CACGCCACCGATCT
GTTCTG 3’; Reverse primer: 5’ GCGCTGCGCCATCACTC 3’. The limit of detection was 10
MNoV genome copies/μL. MNoV genome copies detected in tissues were normalized to the
housekeeping gene β-β-actin which was detected using murine β-actin oligonucleotides:
Probe: 6-JOEN-CACCAGTTC /ZEN/ GCCATGGATGACGA-IABkFQ 3’; Forward primer: 5’
GCT CCT TCG TTG CCG GTC CA 3’; Reverse primer: 5’ TTG CAC ATG CCG GAG CCG
TT 3’. The actin limit of detection for qPCR was 100 copies/μL. Undetectable MNoV genomes
were set at 0.0001 relative to actin. For HNoV GII.4 qPCR, the primer pair COG2R /QNIF2d
and probe QNIFS were used[54]. A standard generated using a 10-fold dilution series of a
recombinant HuNoV RNA transcript was used to quantitate viral genome equivalents in RNA
samples from GII.4 infected HIEs.
Flow cytometry
BMDMs were harvested after mock-inoculation or infection with MNoV. Cells were pelleted
by centrifugation at 200 x g for 5 min and suspended in 250μL of Cytofix/Cytoperm (BD Bio-
sciences) for 20 min at RT. Cells were washed twice with perm/wash buffer (PWB), suspended
in staining buffer containing rabbit anti-NS1/2 antibody (1:1000; kind gift of Vernon Ward).
The cells were incubated with antibody for 30 min at RT, pelleted and washed twice. The cells
were suspended in staining buffer containing donkey anti-rabbit alexa fluor 647 (1:500, Life
Technologies #A31573) and incubated for 30 min in the dark. The cells were pelleted and
washed twice with PWB buffer. Cells were suspended in FACS buffer. Flow cytometry was per-
formed on a MACSQuant Analyzer 10 (Miltenyi Biotec, Somerville, MA) and analyzed using
FlowJo v10 (FlowJo LLC, Ashland, OR).
Mouse CD300 overexpression
HeLa cells were seeded at 400,000 cells per well in a 6-well plate and grown for 24 hours.
Murine CD300lf and CD300ld (pcDNA3.4) were transiently transfected into HeLa cells with
Trans-It LT1 (Mirus Bio, Madison, WI) according to manufacturer instructions[15]. MNoV
was added to transfected HeLa cells at a MOI of 5 and incubated for 24 hours at 37˚C. Cells
were harvested using Trypsin-EDTA and resuspended in FACS buffer (PBS containing 10%
FBS and 2mM EDTA) and stained with anti-CD300lf PE clone Tx70 (1:100; BioLegend,
#132704) or anti-CD300ld PE clone Tx69 (1:100, BioLegend, #139605). Cells were then stained
intracellularly with guinea pig anti-NS6/7 (kind gift from Kim Green) and goat anti-guinea pig
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AlexaFluor 647 (1:500, Life Technologies, #A21450). Cells were then washed twice with PWB
and then resuspended in FACS buffer.
Neutralization assay
Cd300lf-/- or Cd300lf+/- mice were infected PO with 106 PFU MNoVCW3 and terminally bled
via cardiac puncture at 14 dpi. Whole blood was collected in an EDTA Microtainer tube (BD)
and pelleted at 5800 x g for 10 min. Plasma was removed and stored at 4˚C until use. BV2 cells
were seeded at 20,000 cells in 50μL per well in a 96-cell plate and incubated at 37˚C. Sera were
serially diluted in D10 with an initial dilution 1:9 and with five subsequent three-fold dilutions.
Then, 105 PFU of MNoVCW3 was added to each well and mixtures were gently rocked for 30
min at room temperature (RT) and then added to BV2 cells. After 48 hours, 25μL of CellTiter-
Glo was added to each well and luminescence was detected on a luminometer. Experiments
were performed in duplicate with at least three independent replicates.
MNoV-specific ELISA
In a 96-well MaxiSorp plate, 100μL of two-fold serially diluted IgG (starting at 12.5ng/mL) and
IgM (starting at 25ng/mL) was used as standard controls and MNoVCR6 was used to coat the
plate overnight at 4˚C. The plate was then washed three times with 300μL wash buffer (0.05%
Tween-20 in PBS) and then blocked with 100μL of blocking solution (1% BSA in PBS) for 1
hour at RT. After washing 3 times, 50μL of sample at appropriate dilutions in blocking solution
was added to each well and incubated for 2 hours at RT. The plate was further washed three
times and 50μL of anti-mouse IgG-HRP (A3673, Sigma-Aldrich) or anti-mouse IgM-HRP
(A8786, Sigma-Aldrich) diluted in blocking solution was added to each well, then incubated
for 2 hours at RT. Wells were washed three times, and then 40μL of ELISA TMB substrate
solution (eBioscience, San Diego, CA) was added to each. Plates were incubated for 20 min,
then 20μL of stop solution (2N H2SO4) added and OD determined at 450 nm and reference
wavelength 570 nm.
ELISA for HuNoV VLPs binding to PGM
Pig gastric mucin (Sigma-Aldrich) was immobilized at 10 μg/ml in PBS on 96-well-plate at
4˚C overnight. Wells were washed with PBS-0.05% Tween 20 (PBS-T) three times. After block-
ing with 5% non-fat milk at RT for 1 hour, plates were washed once with PBS-T. Fc-huCD300
proteins (10 μg/ml) were mixed with purified HuNoV VLPs at indicated concentrations and
then added and incubated for 1 hour at RT. The wells were washed three times with PBS-T fol-
lowed by addition of rabbit anti-VP1 sera diluted in PBS (1:2000). Wells were incubated at RT
for 1 hour, followed by washing with PBS-T three times as described previously[44]. Secondary
goat anti-rabbit-HRP diluted in PBS were added and incubated for 1 hour. After five washes,
TMB substrate was added, and 2M H2SO4 was applied to stop the reaction. Absorbance at 450
nm was measured.
Statistical analysis
All statistical analysis was performed in Prism GraphPad version 8 (San Diego, CA). Error
bars represent the standard error of the mean unless otherwise indicated. Mann-Whitney tests
were performed for all non-normally distributed data whereas normally distributed data was
analyzed using Student’s T-tests. All statistical tests were two-sided. Virus heat inactivation
was analyzed using a one-way ANOVA. Survival experiments were analyzed by Kaplan-Meier
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survival curves. A p-value of<0.05 was considered significant (� p-value<0.05, �� p-
value<0.01, ��� p-value<0.001, ���� p-value<0.0001).
Supporting information
S1 Fig. Tree and VP1 alignment showing CD300 interacting sites. VP1 is the major struc-
tural protein of MNoV and is comprised of a shell and protruding domain. The complete VP1
sequence of MNoV strains CW3, CR6, CR3, CR7, WU23, MNV3, and S99 were aligned. The
VP1 shell domain comprises the core of the virion and is sufficient for virion assembly. The
protruding domain mediates binding to CD300lf and bile salts and is comprised of discontinu-
ous P1 and P2 subdomains. The CD300lf and secondary bile acid (GCDCA) binding sites are
highlighted as is the F514I mutation which emerged during infection of Cd300l+/-Stat1-/- and
Cd300lf-/-Stat1-/- mice13. Secondary structures labeled as alpha-helices (α), 310-helices (η), and
beta-strands (β). The number following the annotation is the numerical order of that second-
ary structure. Helices are displayed as squiggles and strands are represented by a forward mov-
ing arrow under the annotation. TT = strict β-turns and TTT = strict α turns.
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